Allarity Therapeutics Inc Asset Resilience Ratio
Allarity Therapeutics Inc asset resilience ratio. Allarity Therapeutics Inc (ALLR) has an Asset Resilience Ratio of 0.32% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Allarity Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Allarity Therapeutics Inc (2021–2024)
Asset resilience ratio of Allarity Therapeutics Inc from 2021 to 2024. This chart shows how Allarity Therapeutics Inc's Asset Resilience Ratio has changed over time. Read ALLR total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Allarity Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALLR total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $72.00K | 0.32% |
| Total Liquid Assets | $72.00K | 0.32% |
Asset Resilience Insights
- Limited Liquidity: Allarity Therapeutics Inc maintains only 0.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Allarity Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Allarity Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Allarity Therapeutics Inc Asset Resilience Ratio by Year (2021–2024)
Allarity Therapeutics Inc asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Allarity Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.32% | $72.00K | $22.65 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $14.54 Million | -- |
| 2021-12-31 | 0.71% | $350.00K | $49.63 Million | -- |
About Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead d… Read more